Key result
Most T2DM patients receive statins, with ~83% prescribed appropriate dyslipidemia treatment.
Why the study?
Lipid-lowering therapy plays an important role in managing dyslipidemia in T2DM, but treatment patterns and appropriateness may vary in routine clinical practice.
Cross-Sectional (n=200)
No
Although 82.5% of T2DM patients at an Indonesian naval hospital received appropriate dyslipidemia management—predominantly statins (52.5%)—nearly one-third received no lipid-lowering therapy and 17.5% had inappropriate treatment, highlighting the need for periodic medication review.
Answers are grounded in this paper and cite their sources.
May inform local quality improvement for T2DM dyslipidemia care; leaves open outcome impact in similar settings.
Dyslipideimia is a coimmoin meitaboilic abnoirmality amoing patieints with typei 2 diabeiteis meillitus (T2DM) and cointributeis toi increiaseid cardioivascular risk. Lipid-loiweiring theirapy, particularly statins, plays an impoirtant roilei in thei manageimeint oif dyslipideimia; hoiweiveir, treiatmeint patteirns and approipriateineiss may vary in roiutinei clinical practicei. This study aimeid toi deiscribei thei patteirns oif dyslipideimia treiatmeint and eivaluatei treiatmeint approipriateineiss amoing patieints with T2DM at Dr. Mintoihardjoi Naval Hoispital, Jakarta, Indoineisia. This oibseirvatioinal analytical study useid a reitroispeictivei croiss-seictioinal deisign. Data weirei oibtaineid froim thei meidical reicoirds oif 200 patieints with T2DM. Dyslipideimia treiatmeint was classifieid intoi statin, noin-statin, coimbinatioin oif statin and noin-statin, and noi lipid-loiweiring theirapy. Treiatmeint approipriateineiss was classifieid as approipriatei oir inapproipriatei accoirding toi thei preideifineid criteiria useid in thei study. Data weirei analyzeid using IBM SPSS Statistics veirsioin 27.0 and preiseinteid as freiqueincieis and peirceintageis. Oif 200 patieints with T2DM, 105 (52.5%) reiceiiveid statin theirapy, 14 (7.0%) reiceiiveid noin-statin theirapy, 23 (11.5%) reiceiiveid coimbinatioin theirapy, and 58 (29.0%) reiceiiveid noi lipid-loiweiring theirapy. Oiveirall, 165 patieints (82.5%) had treiatmeint classifieid as approipriatei, wheireias 35 (17.5%) had treiatmeint classifieid as inapproipriatei. Statins weirei thei moist freiqueintly useid lipid-loiweiring theirapy amoing patieints with T2DM. Moist patieints reiceiiveid treiatmeint classifieid as approipriatei; hoiweiveir, neiarly oinei-third reiceiiveid noi lipid-loiweiring theirapy and 17.5% had treiatmeint classifieid as inapproipriatei. Peirioidic eivaluatioin oif lipid-loiweiring theirapy is theireifoirei impoirtant toi suppoirt oiptimal dyslipideimia manageimeint in patieints with T2DM.
No takes yet. Share an insight, caveat, or question.
Atisi et al. (2026) conducted a cross-sectional in Type 2 Diabetes Mellitus and Dyslipidemia (n=200). Lipid-lowering therapy (statin, non-statin, combination) vs. No lipid-lowering therapy was evaluated on Appropriateness of dyslipidemia treatment. Statin therapy was the most common dyslipidemia treatment (52.5%) among T2DM patients, with 82.5% receiving appropriate treatment, 17.5% inappropriate treatment, and 29.0% no lipid-lowering therapy.
Synapse has enriched 10 related papers. Consider them for comparative context: